MedCity News
DECEMBER 25, 2023
Current billing practices do not adequately meet the needs of consumers, providers or payers. While there is no magic wand, reinventing billing processes in the US will require measures that strengthen consumer protection, and continued policy change towards fairer drug pricing and increased price transparency of provider service costs.
Pharmaceutical Technology
DECEMBER 25, 2023
Opaganib is under clinical development by RedHill Biopharma and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
DECEMBER 25, 2023
Last month at a conference, AdventHealth CEO Terry Shaw shared some employee retention strategies used at his health system. He stressed the importance of gathering employee feedback and using it to give them the changes they need. This month, MedCity News followed up with AdventHealth to get a better picture of what these strategies look like in practice.
Pharmaceutical Technology
DECEMBER 25, 2023
Ribociclib succinate is under clinical development by Novartis and currently in Phase II for Oligodendroglioma.
MedCity News
DECEMBER 25, 2023
Executives at LRVHealth expect to see a continued focus on generative AI, increased enrollment in Medicare Advantage and more in 2024.
Pharmaceutical Technology
DECEMBER 25, 2023
Efineptakin alfa is under clinical development by NeoImmuneTech and currently in Phase II for Solid Tumor.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
DECEMBER 25, 2023
Disitamab vedotin is under clinical development by RemeGen and currently in Phase I for Cervical Cancer.
Pharmaceutical Commerce
DECEMBER 25, 2023
This year’s PC Podcast episodes ranged in topic, from DSCSA compliance to pharmacovigilance.
Pharmaceutical Technology
DECEMBER 25, 2023
HCW-9218 is under clinical development by HCW Biologics and currently in Phase I for Ovarian Cancer.
PharmExec
DECEMBER 25, 2023
These stories graced the cover of Pharmaceutical Executive this year
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
DECEMBER 25, 2023
Cabometyx is under clinical development by Exelixis and currently in Phase II for Gastric Cancer.
Pharmacy Times
DECEMBER 25, 2023
From newsworthy moments to groundbreaking research, these were the most-read Alzheimer disease-related articles on Pharmacy Times in 2023.
Pharmaceutical Technology
DECEMBER 25, 2023
ZB-131 is under clinical development by ZielBio and currently in Phase II for Gallbladder Cancer.
Pharmacy Times
DECEMBER 25, 2023
From newsworthy moments to groundbreaking research, these were the most-read pharmacy technician-related articles on Pharmacy Times in 2023.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
DECEMBER 25, 2023
ION-537 is under clinical development by Ionis Pharmaceuticals and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Pharmacy Times
DECEMBER 25, 2023
From newsworthy moments to groundbreaking research, these were the most-read biosimilar-related articles on Pharmacy Times in 2023.
Pharmaceutical Technology
DECEMBER 25, 2023
Cusatuzumab is under clinical development by OncoVerity and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
Pharmaceutical Technology
DECEMBER 25, 2023
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharmaceutical Technology
DECEMBER 25, 2023
Magrolimab is under clinical development by Gilead Sciences and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer.
Pharmaceutical Technology
DECEMBER 25, 2023
Sym-023 is under clinical development by Les Laboratoires Servier and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC).
Pharmaceutical Technology
DECEMBER 25, 2023
BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Central Nervous System (CNS) Tumor.
Pharmaceutical Technology
DECEMBER 25, 2023
Y-101D is under clinical development by Wuhan YZY Biopharma and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC).
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmaceutical Technology
DECEMBER 25, 2023
Dabrafenib mesylate is under clinical development by Novartis and currently in Phase II for Gastrointestinal Stromal Tumor (GIST).
Pharmaceutical Technology
DECEMBER 25, 2023
BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Metastatic Colorectal Cancer.
Pharmaceutical Technology
DECEMBER 25, 2023
Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Metastatic Biliary Tract Cancer.
Pharmaceutical Technology
DECEMBER 25, 2023
Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Atopic Keratoconjunctivitis.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Pharmaceutical Technology
DECEMBER 25, 2023
BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.
Pharmaceutical Technology
DECEMBER 25, 2023
Capivasertib is under clinical development by AstraZeneca and currently in Phase III for Triple-Negative Breast Cancer (TNBC).
Pharmaceutical Technology
DECEMBER 25, 2023
Taladegib is under clinical development by Endeavor BioMedicines and currently in Phase II for Idiopathic Pulmonary Fibrosis.
Pharmaceutical Technology
DECEMBER 25, 2023
ADCT-901 is under clinical development by ADC Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC).
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
109 
Let's personalize your content